Senti Biosciences (NASDAQ:SNTI) Announces Earnings Results

Senti Biosciences (NASDAQ:SNTI) issued its earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.22, FiscalAI reports.

Senti Biosciences Stock Up 8.5%

Shares of NASDAQ SNTI traded up $0.08 during trading hours on Thursday, hitting $1.05. 513,178 shares of the stock were exchanged, compared to its average volume of 195,320. The company has a market cap of $32.54 million, a PE ratio of -0.33 and a beta of 2.09. The firm has a fifty day moving average price of $0.95 and a 200-day moving average price of $1.23. Senti Biosciences has a 12 month low of $0.77 and a 12 month high of $3.88.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in Senti Biosciences during the 4th quarter valued at about $40,000. Virtu Financial LLC acquired a new position in Senti Biosciences during the 4th quarter valued at approximately $46,000. Citadel Advisors LLC acquired a new position in Senti Biosciences during the 3rd quarter valued at approximately $117,000. Geode Capital Management LLC increased its stake in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in Senti Biosciences during the 2nd quarter valued at approximately $1,883,000. 25.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a report on Tuesday, April 21st. Finally, Chardan Capital reduced their price target on shares of Senti Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.